Header Logo

Connection

COLIN P DINNEY to Aged

Back to Details
This is a "connection" page, showing publications COLIN P DINNEY has written about Aged.
COLIN P DINNEY
Connection Strength
1.143
Aged
  1. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
    View in: PubMed
    Score: 0.032
  2. Intravesical rAd-IFNa/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20; 35(30):3410-3416.
    View in: PubMed
    Score: 0.025
  3. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus. 2017 12; 3(6):577-583.
    View in: PubMed
    Score: 0.025
  4. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon a2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. Ann Surg Oncol. 2016 11; 23(12):4110-4114.
    View in: PubMed
    Score: 0.024
  5. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014 Jan; 191(1):40-7.
    View in: PubMed
    Score: 0.019
  6. Phase I trial of intravesical recombinant adenovirus mediated interferon-a2b formulated in Syn3 for Bacillus Calmette-Gu?rin failures in nonmuscle invasive bladder cancer. J Urol. 2013 Sep; 190(3):850-6.
    View in: PubMed
    Score: 0.019
  7. Plasma microRNA profiles for bladder cancer detection. Urol Oncol. 2013 Nov; 31(8):1701-8.
    View in: PubMed
    Score: 0.018
  8. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Gu?rin. Urol Oncol. 2013 Nov; 31(8):1635-42.
    View in: PubMed
    Score: 0.018
  9. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Gu?rin therapy for bladder cancer: results of a prospective trial. J Urol. 2012 Mar; 187(3):862-7.
    View in: PubMed
    Score: 0.017
  10. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int. 2011 Oct; 108(7):1119-23.
    View in: PubMed
    Score: 0.016
  11. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 2011 Mar; 107(6):898-904.
    View in: PubMed
    Score: 0.016
  12. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer. 2010 Oct 01; 116(19):4513-9.
    View in: PubMed
    Score: 0.016
  13. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol. 2008 Jan; 179(1):353-8.
    View in: PubMed
    Score: 0.013
  14. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer. 2007 Aug 15; 110(4):764-9.
    View in: PubMed
    Score: 0.013
  15. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol. 2006 Jun; 175(6):2058-62.
    View in: PubMed
    Score: 0.012
  16. Correlation between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-based study. Cancer. 2005 Sep 01; 104(5):975-84.
    View in: PubMed
    Score: 0.011
  17. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol. 2004 Feb; 171(2 Pt 1):570-4.
    View in: PubMed
    Score: 0.010
  18. Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol. 2003 Sep-Oct; 21(5):327-33.
    View in: PubMed
    Score: 0.010
  19. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol. 2003 Jun 15; 21(12):2247-53.
    View in: PubMed
    Score: 0.010
  20. Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. Urology. 2003 Jun; 61(6):1151-5.
    View in: PubMed
    Score: 0.010
  21. Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. J Urol. 2022 Mar; 207(3):551-558.
    View in: PubMed
    Score: 0.009
  22. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res. 2001 Sep; 7(9):2840-53.
    View in: PubMed
    Score: 0.008
  23. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. J Urol. 2022 01; 207(1):70-76.
    View in: PubMed
    Score: 0.008
  24. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World J Urol. 2021 Dec; 39(12):4345-4354.
    View in: PubMed
    Score: 0.008
  25. Progression of Disease after Bacillus Calmette-Gu?rin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol. 2021 11; 206(5):1258-1267.
    View in: PubMed
    Score: 0.008
  26. What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs. Urology. 2021 11; 157:181-187.
    View in: PubMed
    Score: 0.008
  27. Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center. World J Urol. 2021 Nov; 39(11):4143-4149.
    View in: PubMed
    Score: 0.008
  28. Time interval from transurethral resection of bladder tumour to bacille Calmette-Gu?rin induction does not impact therapeutic response. BJU Int. 2021 11; 128(5):634-641.
    View in: PubMed
    Score: 0.008
  29. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. J Urol. 2021 09; 206(3):548-557.
    View in: PubMed
    Score: 0.008
  30. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. J Urol. 2021 Sep; 206(3):577-585.
    View in: PubMed
    Score: 0.008
  31. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. BJU Int. 2021 11; 128(5):568-574.
    View in: PubMed
    Score: 0.008
  32. Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. Urol Oncol. 2021 05; 39(5):301.e17-301.e28.
    View in: PubMed
    Score: 0.008
  33. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Gu?rin: Implications for Clinical Trial Design. J Urol. 2021 06; 205(6):1612-1621.
    View in: PubMed
    Score: 0.008
  34. Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. Urol Oncol. 2021 04; 39(4):237.e1-237.e5.
    View in: PubMed
    Score: 0.008
  35. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu?rin. BJU Int. 2021 07; 128(1):65-71.
    View in: PubMed
    Score: 0.008
  36. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res. 2000 Dec; 6(12):4866-73.
    View in: PubMed
    Score: 0.008
  37. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int. 2021 05; 127(5):528-537.
    View in: PubMed
    Score: 0.008
  38. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
    View in: PubMed
    Score: 0.008
  39. Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. J Sex Med. 2020 10; 17(10):1995-2004.
    View in: PubMed
    Score: 0.008
  40. Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. Am J Clin Pathol. 2020 07 07; 154(2):208-214.
    View in: PubMed
    Score: 0.008
  41. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urol Oncol. 2020 07; 38(7):639.e1-639.e9.
    View in: PubMed
    Score: 0.008
  42. Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. Urol Oncol. 2020 04; 38(4):247-254.
    View in: PubMed
    Score: 0.008
  43. Rationale for bladder-sparing surgery in patients with locally advanced colorectal carcinoma. Cancer. 1999 Dec 01; 86(11):2212-6.
    View in: PubMed
    Score: 0.007
  44. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin Cancer Res. 2020 02 15; 26(4):882-891.
    View in: PubMed
    Score: 0.007
  45. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020 04; 77(4):420-433.
    View in: PubMed
    Score: 0.007
  46. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019 05 07; 27(6):1781-1793.e4.
    View in: PubMed
    Score: 0.007
  47. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World J Urol. 2019 Dec; 37(12):2691-2698.
    View in: PubMed
    Score: 0.007
  48. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol. 2019 06; 37(6):354.e19-354.e26.
    View in: PubMed
    Score: 0.007
  49. Overall survival in older patients with cancer. BMJ Support Palliat Care. 2020 Mar; 10(1):25-35.
    View in: PubMed
    Score: 0.007
  50. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Eur Urol Oncol. 2019 05; 2(3):286-293.
    View in: PubMed
    Score: 0.007
  51. Accuracy of High-Frequency Endoluminal Ultrasonography for Clinical Staging of Upper Tract Urothelial Carcinoma. J Endourol. 2018 09 12; 32(9):806-811.
    View in: PubMed
    Score: 0.007
  52. Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. Eur Urol Focus. 2020 01 15; 6(1):88-94.
    View in: PubMed
    Score: 0.007
  53. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. World J Urol. 2019 Jan; 37(1):165-172.
    View in: PubMed
    Score: 0.007
  54. Urine cell-based DNA methylation classifier for monitoring bladder cancer. Clin Epigenetics. 2018; 10:71.
    View in: PubMed
    Score: 0.007
  55. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol. 2018 Dec; 36(12):2027-2034.
    View in: PubMed
    Score: 0.007
  56. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol. 2018 09; 79:57-65.
    View in: PubMed
    Score: 0.007
  57. Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. BJU Int. 2018 07; 122(1):89-98.
    View in: PubMed
    Score: 0.007
  58. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998 Apr; 159(4):1163-7.
    View in: PubMed
    Score: 0.007
  59. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J Urol. 1998 Apr; 159(4):1168-73.
    View in: PubMed
    Score: 0.007
  60. Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy. Surg Innov. 2018 Jun; 25(3):242-250.
    View in: PubMed
    Score: 0.007
  61. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1998 Mar; 159(3):792-5.
    View in: PubMed
    Score: 0.007
  62. Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. Eur Urol Focus. 2019 07; 5(4):664-675.
    View in: PubMed
    Score: 0.007
  63. Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. Am J Clin Nutr. 2018 02 01; 107(2):208-216.
    View in: PubMed
    Score: 0.007
  64. Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int J Cancer. 2018 05 01; 142(9):1797-1804.
    View in: PubMed
    Score: 0.007
  65. Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Support Care Cancer. 2018 May; 26(5):1561-1568.
    View in: PubMed
    Score: 0.006
  66. Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. Urology. 1997 Nov; 50(5):673-7.
    View in: PubMed
    Score: 0.006
  67. Effects of thiazolidinedione in patients with active bladder cancer. BJU Int. 2018 02; 121(2):244-251.
    View in: PubMed
    Score: 0.006
  68. Risk factors for falls in older patients with cancer. BMJ Support Palliat Care. 2018 Mar; 8(1):34-37.
    View in: PubMed
    Score: 0.006
  69. Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. J Geriatr Oncol. 2018 01; 9(1):81-83.
    View in: PubMed
    Score: 0.006
  70. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol. 2017 09; 31(9):946-953.
    View in: PubMed
    Score: 0.006
  71. Dose dense MVAC prior to radical cystectomy: a real-world experience. World J Urol. 2017 Nov; 35(11):1729-1736.
    View in: PubMed
    Score: 0.006
  72. Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: results of a contemporary cystectomy series from M. D. Anderson Cancer Center. J Urol. 1997 Jun; 157(6):2120-3.
    View in: PubMed
    Score: 0.006
  73. Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. Am J Clin Pathol. 2017 May 01; 147(5):500-506.
    View in: PubMed
    Score: 0.006
  74. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus. 2018 09; 4(5):720-724.
    View in: PubMed
    Score: 0.006
  75. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int. 2017 05; 119(5):684-691.
    View in: PubMed
    Score: 0.006
  76. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine. 2016 Oct; 12:105-117.
    View in: PubMed
    Score: 0.006
  77. Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional study. Medicine (Baltimore). 2016 Aug; 95(31):e4500.
    View in: PubMed
    Score: 0.006
  78. Complications of radical cystectomy: impact of the timing of perioperative chemotherapy. Urology. 1996 Jun; 47(6):826-30.
    View in: PubMed
    Score: 0.006
  79. Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer. Eur Urol Focus. 2017 04; 3(2-3):258-264.
    View in: PubMed
    Score: 0.006
  80. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Gu?rin Therapy: Implication for Clinical Trial Design. Eur Urol. 2016 11; 70(5):778-785.
    View in: PubMed
    Score: 0.006
  81. The risk of upper tract recurrence following cystectomy in patients with transitional cell carcinoma involving the distal ureter. J Urol. 1996 Feb; 155(2):501-3.
    View in: PubMed
    Score: 0.006
  82. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urol Oncol. 2016 Feb; 34(2):59.e1-8.
    View in: PubMed
    Score: 0.006
  83. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-na?ve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016 05; 69(5):855-62.
    View in: PubMed
    Score: 0.006
  84. Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. World J Urol. 2016 May; 34(5):695-701.
    View in: PubMed
    Score: 0.006
  85. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol. 2015 Dec; 46(12):1808-14.
    View in: PubMed
    Score: 0.006
  86. Genetic Variants in the Wnt/?-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk. J Urol. 2015 Dec; 194(6):1771-6.
    View in: PubMed
    Score: 0.005
  87. Novel fluorescence in?situ hybridization-based definition of bacille Calmette-Gu?rin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU Int. 2016 May; 117(5):754-60.
    View in: PubMed
    Score: 0.005
  88. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Gu?rin. Eur Urol. 2016 02; 69(2):197-200.
    View in: PubMed
    Score: 0.005
  89. Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA Polymorphisms. Cancer Prev Res (Phila). 2015 Jul; 8(7):607-13.
    View in: PubMed
    Score: 0.005
  90. Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder Cancer. Ann Surg Oncol. 2015 Nov; 22(12):4104-10.
    View in: PubMed
    Score: 0.005
  91. Management of transitional cell carcinoma involving von Brunn's nests. J Urol. 1995 Mar; 153(3 Pt 2):944-9.
    View in: PubMed
    Score: 0.005
  92. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014 Dec; 142(6):864-71.
    View in: PubMed
    Score: 0.005
  93. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb; 67(2):241-9.
    View in: PubMed
    Score: 0.005
  94. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015 Apr; 193(4):1129-34.
    View in: PubMed
    Score: 0.005
  95. Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. Urology. 2014 Nov; 84(5):1147-51.
    View in: PubMed
    Score: 0.005
  96. Genome-wide association study identifies variants in casein kinase II (CSNK2A2) to be associated with leukocyte telomere length in a Punjabi Sikh diabetic cohort. Circ Cardiovasc Genet. 2014 Jun; 7(3):287-95.
    View in: PubMed
    Score: 0.005
  97. Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review. BJU Int. 2014 May; 113(5b):E28-33.
    View in: PubMed
    Score: 0.005
  98. Therapy and prognosis for male anterior urethral carcinoma: an update. Urology. 1994 Apr; 43(4):506-14.
    View in: PubMed
    Score: 0.005
  99. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol. 2014 Jul; 45(7):1466-72.
    View in: PubMed
    Score: 0.005
  100. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014 Jun 15; 120(12):1794-9.
    View in: PubMed
    Score: 0.005
  101. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Feb 10; 25(2):152-65.
    View in: PubMed
    Score: 0.005
  102. Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes. Int Braz J Urol. 2013 Nov-Dec; 39(6):817-22.
    View in: PubMed
    Score: 0.005
  103. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther. 2013 Jul; 12(7):1245-54.
    View in: PubMed
    Score: 0.005
  104. Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk. Br J Cancer. 2013 Jun 11; 108(11):2372-80.
    View in: PubMed
    Score: 0.005
  105. Lymphoepithelioma of the bladder: a clinicopathological study of 3 cases. J Urol. 1993 Apr; 149(4):840-1.
    View in: PubMed
    Score: 0.005
  106. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013 May; 189(5):1656-61.
    View in: PubMed
    Score: 0.005
  107. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer. 2013 Feb 01; 119(3):540-7.
    View in: PubMed
    Score: 0.005
  108. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013 Aug; 64(2):307-13.
    View in: PubMed
    Score: 0.004
  109. Analysis of imaging modalities, staging systems, and prognostic indicators for renal cell carcinoma. Urology. 1992 Feb; 39(2):122-9.
    View in: PubMed
    Score: 0.004
  110. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One. 2012; 7(1):e30206.
    View in: PubMed
    Score: 0.004
  111. Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. World J Urol. 2012 Dec; 30(6):753-9.
    View in: PubMed
    Score: 0.004
  112. Comprehensive pathway-based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of bladder cancer. Cancer. 2012 Jan 01; 118(1):205-15.
    View in: PubMed
    Score: 0.004
  113. Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. Urol Int. 2011; 87(1):42-8.
    View in: PubMed
    Score: 0.004
  114. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol. 2013 May; 31(4):480-6.
    View in: PubMed
    Score: 0.004
  115. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology. 2011 Jul; 78(1):61-7.
    View in: PubMed
    Score: 0.004
  116. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol. 2011 Apr; 185(4):1216-21.
    View in: PubMed
    Score: 0.004
  117. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol. 2011 Feb; 185(2):456-61.
    View in: PubMed
    Score: 0.004
  118. Upper tract urothelial carcinoma: impact of time to surgery. Urol Oncol. 2012 May-Jun; 30(3):266-72.
    View in: PubMed
    Score: 0.004
  119. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila). 2010 Oct; 3(10):1235-45.
    View in: PubMed
    Score: 0.004
  120. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol. 2010 Sep; 184(3):888-94.
    View in: PubMed
    Score: 0.004
  121. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010 Sep 01; 16(17):4461-7.
    View in: PubMed
    Score: 0.004
  122. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010 Jul 01; 116(13):3127-34.
    View in: PubMed
    Score: 0.004
  123. Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis. 2010 Aug; 31(8):1387-91.
    View in: PubMed
    Score: 0.004
  124. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol. 2010 Jun; 183(6):2165-70.
    View in: PubMed
    Score: 0.004
  125. Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy. Urology. 2010 Dec; 76(6):1419-24.
    View in: PubMed
    Score: 0.004
  126. The role of radical cystectomy in patients with clinical T4b bladder cancer. Urol Oncol. 2011 Mar-Apr; 29(2):157-61.
    View in: PubMed
    Score: 0.004
  127. Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer. Cancer Prev Res (Phila). 2010 Apr; 3(4):505-17.
    View in: PubMed
    Score: 0.004
  128. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010 May; 105(10):1402-12.
    View in: PubMed
    Score: 0.004
  129. Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. J Urol. 2010 Mar; 183(3):929-34.
    View in: PubMed
    Score: 0.004
  130. Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. Cancer. 2010 Jan 15; 116(2):340-6.
    View in: PubMed
    Score: 0.004
  131. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol. 2010 Jan; 183(1):87-93.
    View in: PubMed
    Score: 0.004
  132. Management of urethral recurrence after orthotopic urinary diversion. BJU Int. 2010 Jul; 106(1):56-61.
    View in: PubMed
    Score: 0.004
  133. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis. 2009 Dec; 30(12):2047-52.
    View in: PubMed
    Score: 0.004
  134. Cardiac history and risk of post-cystectomy cardiac complications. Urology. 2009 Nov; 74(5):1085-9.
    View in: PubMed
    Score: 0.004
  135. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010 Feb; 57(2):300-9.
    View in: PubMed
    Score: 0.004
  136. Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2009 Jul; 18(7):2090-7.
    View in: PubMed
    Score: 0.004
  137. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol. 2009 Oct; 40(10):1448-52.
    View in: PubMed
    Score: 0.004
  138. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009 Jun 01; 27(16):2592-7.
    View in: PubMed
    Score: 0.004
  139. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology. 2009 Jan; 73(1):147-52.
    View in: PubMed
    Score: 0.003
  140. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer. 2008 Jun; 112(11):2467-74.
    View in: PubMed
    Score: 0.003
  141. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. J Urol. 2008 Jul; 180(1):164-7; discussion 167.
    View in: PubMed
    Score: 0.003
  142. Plasma vitamins E and A and risk of bladder cancer: a case-control analysis. Cancer Causes Control. 2008 Nov; 19(9):981-92.
    View in: PubMed
    Score: 0.003
  143. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest. 2008 Jul; 88(7):694-721.
    View in: PubMed
    Score: 0.003
  144. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res. 2008 Apr 01; 68(7):2530-7.
    View in: PubMed
    Score: 0.003
  145. Clinical model of cost of bladder cancer in the elderly. Urology. 2008 Mar; 71(3):519-25.
    View in: PubMed
    Score: 0.003
  146. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.
    View in: PubMed
    Score: 0.003
  147. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol. 2007 Dec; 178(6):2302-6; discussion 2307.
    View in: PubMed
    Score: 0.003
  148. Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology. 2007 Sep; 70(3):473-6.
    View in: PubMed
    Score: 0.003
  149. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol. 2007 Oct; 178(4 Pt 1):1492-6.
    View in: PubMed
    Score: 0.003
  150. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology. 2007 Aug; 70(2):252-6.
    View in: PubMed
    Score: 0.003
  151. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer. 2007 Jul 01; 110(1):62-7.
    View in: PubMed
    Score: 0.003
  152. Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk. Int J Cancer. 2007 May 15; 120(10):2208-13.
    View in: PubMed
    Score: 0.003
  153. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol. 2007 Sep; 52(3):769-74.
    View in: PubMed
    Score: 0.003
  154. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol. 2007 Jan-Feb; 25(1):38-45.
    View in: PubMed
    Score: 0.003
  155. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int. 2006 Dec; 98(6):1176-80.
    View in: PubMed
    Score: 0.003
  156. Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. Carcinogenesis. 2007 Mar; 28(3):698-703.
    View in: PubMed
    Score: 0.003
  157. Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer. 2006 Oct 01; 107(7):1491-5.
    View in: PubMed
    Score: 0.003
  158. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006 Sep; 68(3):549-53.
    View in: PubMed
    Score: 0.003
  159. Personal permanent hair dye use is not associated with bladder cancer risk: evidence from a case-control study. Cancer Epidemiol Biomarkers Prev. 2006 Sep; 15(9):1746-9.
    View in: PubMed
    Score: 0.003
  160. Bladder cancer risk as modified by family history and smoking. Cancer. 2006 Aug 15; 107(4):705-11.
    View in: PubMed
    Score: 0.003
  161. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol. 2006 Jul; 176(1):53-7; discussion 57.
    View in: PubMed
    Score: 0.003
  162. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006 Mar; 175(3 Pt 1):881-5.
    View in: PubMed
    Score: 0.003
  163. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology. 2006 Mar; 67(3):466-71.
    View in: PubMed
    Score: 0.003
  164. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006 Mar; 78(3):464-79.
    View in: PubMed
    Score: 0.003
  165. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005 Aug 20; 23(24):5746-56.
    View in: PubMed
    Score: 0.003
  166. Roles of tumor suppressor and telomere maintenance genes in cancer and aging--an epidemiological study. Carcinogenesis. 2005 Oct; 26(10):1741-7.
    View in: PubMed
    Score: 0.003
  167. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res. 2005 Feb 15; 11(4):1408-15.
    View in: PubMed
    Score: 0.003
  168. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004 Aug 15; 22(16):3316-22.
    View in: PubMed
    Score: 0.003
  169. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol. 2004 Aug; 172(2):481-4.
    View in: PubMed
    Score: 0.003
  170. Genetic instability in bladder cancer assessed by the comet assay. J Natl Cancer Inst. 2003 Apr 02; 95(7):540-7.
    View in: PubMed
    Score: 0.002
  171. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001 Oct 15; 19(20):4005-13.
    View in: PubMed
    Score: 0.002
  172. Radical cystectomy for invasive bladder cancer in the octogenarian. Oncol Rep. 2001 Jul-Aug; 8(4):723-6.
    View in: PubMed
    Score: 0.002
  173. Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. Diagn Cytopathol. 1999 May; 20(5):285-90.
    View in: PubMed
    Score: 0.002
  174. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol. 1998 Feb; 159(2):394-8.
    View in: PubMed
    Score: 0.002
  175. Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 1997 Oct 01; 39(3):687-95.
    View in: PubMed
    Score: 0.002
  176. Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. J Urol. 1997 Sep; 158(3 Pt 1):806-11.
    View in: PubMed
    Score: 0.002
  177. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Ann Thorac Surg. 1997 Jun; 63(6):1592-600.
    View in: PubMed
    Score: 0.002
  178. The efficacy and complications of salvage cryotherapy of the prostate. J Urol. 1997 Mar; 157(3):921-5.
    View in: PubMed
    Score: 0.002
  179. Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys. 1997 Jan 01; 37(1):41-9.
    View in: PubMed
    Score: 0.002
  180. DNA image analysis of urinary cytology: prediction of recurrent transitional cell carcinoma. Mod Pathol. 1996 May; 9(5):571-8.
    View in: PubMed
    Score: 0.001
  181. Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol. 1996 Apr; 155(4):1241-5.
    View in: PubMed
    Score: 0.001
  182. Sentinel lymph node dissection for penile carcinoma: the M. D. Anderson Cancer Center experience. J Urol. 1995 Dec; 154(6):1999-2003.
    View in: PubMed
    Score: 0.001
  183. The relationship of local control to distant metastasis in muscle invasive bladder cancer. J Urol. 1995 Dec; 154(6):2059-63; discussion 2063-4.
    View in: PubMed
    Score: 0.001
  184. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys. 1995 May 15; 32(2):331-40.
    View in: PubMed
    Score: 0.001
  185. Ultrasound-guided transperineal needle biopsy of the prostate after abdominoperineal resection. J Clin Ultrasound. 1995 May; 23(4):263-5.
    View in: PubMed
    Score: 0.001
  186. Lymphoepithelioma-like carcinoma of the urinary bladder. Am J Surg Pathol. 1994 May; 18(5):466-73.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.